The healthcare insurers organisation ZN said on Friday expensive medicines for the rare diseases Pompe and Fabry must remain in the healthcare package.

The comment comes after the health insurance council CVZ advised the health minister that payments for expensive medicines for these two rare metabolic disorders should be scrapped.
The CVZ said that although the treatment does have an affect, the cost is too high in comparison with the results it delivers.
Complaint
The ZN has now written to the CVZ saying payments should continue and complaining that the advice gives the wrong impression that healthcare insurers are supportive. ‘This is surprising, because healthcare insurers have never discussed the matter,’ says the ZN.
Organisations representing genetics experts, pediatricians and patients already called on health minister Edith Schippers not to act hastily on the advice.
Normally the ZN does not comment on advice on changes to the basic healthcare package but it is making an exception in this case, say press reports.